Population pharmacokinetics and individualized lobaplatin regimen for the treatment of Chinese small cell lung cancer in the elderly. Issue 3 (January 2019)

• Record Type: Journal Article
• Authors: Cheng, Ying; Wu, Lin; Liu, Xiaoqing; Zhao, Yanqiu; Liu, Chunling; Chen, Qun; Sun, Tao; Zheng, Qingshan
• Other Names: Li. Jianfeng section editor.
• Is Part Of: Medicine. Volume 98:Issue 3(2019)
• Publication Date: 2019-01
• Subjects: chemotherapy -- lobaplatin -- plasma concentration -- population pharmacokinetics -- small-cell lung cancer; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000014136
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Background: Lobaplatin (LBP) is a third-generation platinum compound. Material and methods: This prospective study was performed in 7 institutions in 2014–2016. Elderly small cell lung cancer (SCLC) patients (≥65 years old) were divided into 2 groups to receive LBP regimens according to endogenous creatinine clearance rate (Ccr). LBP was administered at 30 and 20 mg/m 2 in groups A (Ccr ≥ 80 ml/min) and B (60 ml/min ⩽ Ccr < 80 ml/min), respectively. The primary endpoint was plasma LBP concentrations. Secondary endpoints were safety and efficacy parameters, including progression-free survival (PFS) and overall survival (OS). Results: One-hundred patients were enrolled. Median PFS and OS in groups A and B were 155 vs170 days and 306 vs 272 days, respectively. The rates of grade III/IV AEs in groups A and B were 60.8% ( n = 31) and 51.0% ( n = 25), respectively. In population pharmacokinetics, the area under the curve (AUC) value for group B was 39% lower than that of group A. With LBP administration based on body surface area (BSA), AUC differences between individuals were small. Conclusion: With Ccr ≥ 60 ml/min, BSA based administration is necessary. Meanwhile, LBP-based regimens are reliable in treating elderly patients with SCLC.